3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Pleural Effusion, Malignant
3
Immunoglobulin Light-chain Amyloidosis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Mycosis Fungoides
2
Lymphoma, Non-Hodgkin
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Urologic Neoplasms
1
Tuberous Sclerosis
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Polycystic Ovary Syndrome
1
Pleural Neoplasms
1
Pancreatic Neoplasms
1
Pain
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Myoma
1
Menstruation Disturbances
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Interventions
Peripheral Blood Stem Cell Transplantation
36
fludarabine phosphate
32
Cyclophosphamide
30
Mycophenolic Acid
26
Whole-Body Irradiation
23
Tacrolimus
22
Cyclosporine
20
Busulfan
16
Antilymphocyte Serum
16
Methotrexate
14
Radiotherapy
13
Filgrastim
12
Flow Cytometry
11
Etoposide
11
Methylprednisolone
8
Melphalan
8
Therapeutics
7
Rituximab
7
Lenalidomide
7
Psychiatric Rehabilitation
6
Cord Blood Stem Cell Transplantation
6
Bortezomib
6
Transplantation
5
Sirolimus
5
Polymerase Chain Reaction
5
Gemcitabine
5
Everolimus
5
Brentuximab Vedotin
5
Alemtuzumab
5
pembrolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sezary Syndrome
×
Doxycycline
×
Clear all
NCT02341209
2021-04-27
CTCL
Rochester General Hospital
Phase 2
Terminated
1 enrolled